AbbVie Inc.
Guidance Including the Impact of Acquired IPR&D and Milestones Expense
(Unaudited)
(in millions, except per share data) | Quarter Ended December 31, 2022 | Full-Year Ended December 31, 2022 | |||||||||||||||||||||||||||||||||
Acquired IPR&D and Milestones Expense | Adjusted Diluted EPS Range | Acquired IPR&D and Milestones Expense | Adjusted Diluted EPS Range | ||||||||||||||||||||||||||||||||
Low | High | Low | High | ||||||||||||||||||||||||||||||||
Previously announced guidance excluding Q4 2022 acquired IPR&D and milestones expense | $ | — | $ | 3.65 | $ | 3.69 | $ | 454 | $ | 13.84 | $ | 13.88 | |||||||||||||||||||||||
Q4 2022 acquired IPR&D and milestones expense | 243 | (0.14) | (0.14) | 243 | (0.14) | (0.14) | |||||||||||||||||||||||||||||
Guidance including Q4 2022 acquired IPR&D and milestones expense | $ | 243 | $ | 3.51 | $ | 3.55 | $ | 697 | $ | 13.70 | $ | 13.74 |
1